Rafferty Asset Management
ATYR

Rafferty Asset Management’s aTyr Pharma ATYR Stock Holding History

Rafferty Asset Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-170,610
Closed -$123K – 1181
2025
Q3 		$123K Buy
+170,610
New +$773K ﹤0.01% 1093

Other funds holding ATYR

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rafferty Asset Management's ATYR Position: Q4 2025 in Review

Rafferty Asset Management sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 170,610 shares — an estimated $123K sold.

Rafferty Asset Management first reported a position in ATYR in Q3 2025 and held it in 1 quarter. The position peaked at $123K in Q3 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

  • Rafferty Asset Management reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
  • Rafferty Asset Management sold 170,610 aTyr Pharma shares in Q4 2025, an estimated $123K.
  • Rafferty Asset Management first reported a position in aTyr Pharma in Q3 2025 and held it in 1 quarter.
  • Rafferty Asset Management's aTyr Pharma position peaked at $123K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on Rafferty Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.